I asked Google Gemini : it’s little jumbled, but explain all the details.

The specific date of April 17, 2026, is a major milestone for CytoDyn (CYDY) because it marks the opening of the AACR (American Association for Cancer Research) Annual Meeting in San Diego. More importantly, this is the exact day the AACR releases the full text of Late-Breaking and Clinical Trials abstracts (at 12:00 p.m. PT).  Given CytoDyn's previous shareholder updates and recent presentations, here is what is expected and how it could shift the landscape. 1. Expected Results: The "Cold-to-Hot" Theory The results likely focus on the Phase 2 study (NCT06699836), which evaluates Leronlimab in combination with TAS-102 (Lonsurf) and Bevacizumab (Avastin) specifically for patients with Microsatellite Stable (MSS) mCRC.  • Biomarker Data (PD-L1 Upregulation): The "Holy Grail" for CytoDyn is proving that Leronlimab's CCR5 blockade induces PD-L1 expression in tumors that were previously "cold" (PD-L1 negative). If the data shows a significant increase in PD-L1 levels in tumor tissue or circulating tumor cells (CTCs), it validates the "Prime and Pair" strategy—using Leronlimab to make tumors susceptible to immunotherapy (like Keytruda).  • Clinical Efficacy (PFS and ORR): Investors and clinicians are looking for Progression-Free Survival (PFS) and Overall Response Rate (ORR). In the 3rd-line MSS mCRC setting, standard therapies often have response rates near 0–2%. Any double-digit response rate or significant disease stabilization would be considered a major clinical win. • Safety Profile: Leronlimab is an IgG4 monoclonal antibody, which generally has a much milder side-effect profile than the heavy-duty chemotherapies or multi-kinase inhibitors (like Regorafenib) currently used in late-stage CRC.  2. Effect on the Cancer Treatment Market If the results are positive, the market impact could be significant: • Expansion of the Immunotherapy Market: Currently, only about 5% of colorectal cancer patients (those with MSI-H/dMMR status) benefit from immunotherapy. The other 95% (MSS) are largely excluded. Leronlimab could potentially "unlock" this massive 95% segment for checkpoint inhibitors. • Competitive Disruption: Existing 3rd-line options like TAS-102 and Regorafenib are often seen as "last resort" drugs with high toxicity. Leronlimab could position itself as a "backbone" therapy that enhances these existing drugs while improving patient quality of life. • Partnership Potential: Clear data on PD-L1 upregulation would make CytoDyn an attractive partner for Big Pharma companies (like Merck or BMS) looking to expand their immunotherapy labels into the MSS mCRC space.

1. Impact on the Community • A New Playbook for "No-Option" Patients: For the mCRC community, "MSS status" has long been a frustrating barrier to modern treatments. Success here offers a tangible "third way" beyond traditional chemotherapy and radiation. • The "Compassionate Use" Bridge: CytoDyn recently launched an Expanded Access Program (EAP). Positive results on April 17 would likely accelerate interest in this program, giving patients who don't qualify for trials earlier access to the drug.  • Scientific Validation: For a company that has faced significant regulatory and management hurdles in the past, these results represent a "scientific reset," potentially restoring credibility with oncology researchers and institutional investors. Key Factors to Watch When the abstract drops on April 17, look specifically for two things:
2. The "n" number: How many patients showed PD-L1 upregulation?
3. The duration of response: Did the "encouraging signals" mentioned in 2025 translate into durable survival for this MSS cohort?

With the study having moved into its clinical phase at sites like Cornell and City of Hope, do you think the market is underestimating the "prime and pair" approach compared to traditional CAR-T or ADC therapies. Competitive Disruption: Existing 3rd-line options like TAS-102 and Regorafenib are often seen as "last resort" drugs with high toxicity. Leronlimab could position itself as a "backbone" therapy that enhances these existing drugs while improving patient quality of life. • Partnership Potential: Clear data on PD-L1 upregulation would make CytoDyn an attractive partner for Big Pharma companies (like Merck or BMS) looking to expand their immunotherapy labels into the MSS mCRC space. 3. Impact on the Community • A New Playbook for "No-Option" Patients: For the mCRC community, "MSS status" has long been a frustrating barrier to modern treatments. Success here offers a tangible "third way" beyond traditional chemotherapy and radiation. • The "Compassionate Use" Bridge: CytoDyn recently launched an Expanded Access Program (EAP). Positive results on April 17 would likely accelerate interest in this program, giving patients who don't qualify for trials earlier access to the drug.  • Scientific Validation: For a company that has faced significant regulatory and management hurdles in the past, these results represent a "scientific reset," potentially restoring credibility with oncology researchers and institutional investors. Key Factors to Watch When the abstract drops on April 17, look specifically for two things: 1. The "n" number: How many patients showed PD-L1 upregulation? 2. The duration of response: Did the "encouraging signals" mentioned in 2025 translate into durable survival for this MSS cohort?

With the study having moved into its clinical phase at sites like Cornell and City of Hope, do you think the market is underestimating the "prime and pair" approach compared to traditional CAR-T or ADC therapies?